RAPH (Raphael Pharmaceutical) 3-Year Book Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RAPH Raphael Pharmaceutical Inc RAPH
24 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Raphael Pharmaceutical 3-Year Book Growth Rate?

Raphael Pharmaceutical RAPH 24 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates RAPH with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 910 Drug Manufacturers companies, Raphael Pharmaceutical ranks worse than 109890% on this metric.

Raphael Pharmaceutical's Book Value per Share for the quarter that ended in Jun. 2026 was $-0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Raphael Pharmaceutical  (OTCPK:RAPH) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Raphael Pharmaceutical 3-Year Book Growth Rate Related Terms

RAPH vs ETST, TXMD, INIS: 3-Year Book Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Raphael Pharmaceutical 3-Year Book Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's 3-Year Book Growth Rate falls into.


RAPH
24GF Score
Raphael Pharmaceutical Inc RAPH
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Raphael Pharmaceutical 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
Raphael Pharmaceutical (RAPH) has a 3-Year Book Growth Rate of 0.00% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Raphael Pharmaceutical and its competitors. According to the industry distribution chart, Raphael Pharmaceutical ranks #999999 out of 910 companies in the Drug Manufacturers industry.
Is Raphael Pharmaceutical's 3-Year Book Growth Rate too high?
Raphael Pharmaceutical's current 3-Year Book Growth Rate is 0.00%. Based on the distribution chart, Raphael Pharmaceutical ranks #999999 out of 910 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Raphael Pharmaceutical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's 3-Year Book Growth Rate compare to ETST and TXMD?
According to the Drug Manufacturers industry distribution chart, Raphael Pharmaceutical ranks #999999 out of 910 companies for 3-Year Book Growth Rate. This places Raphael Pharmaceutical in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 910 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Raphael Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raphael Pharmaceutical's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. Raphael Pharmaceutical's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current 3-Year Book Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Raphael Pharmaceutical Business Description

Address 4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
24GF Score

Get the complete analysis for RAPH

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price